Cullinan Oncology Amends 8-K/A for Corporate Info Update

TL;DR

**Cullinan Oncology filed an 8-K/A to update basic company info, no major news.**

AI Summary

Cullinan Oncology, Inc. (CGEM) filed an 8-K/A on January 8, 2024, to amend a previous filing regarding its 'Results of Operations and Financial Condition.' This amendment primarily updates administrative details, including its current name, 'Cullinan Oncology, Inc.', and its business address at One Main Street, Suite 1350, Cambridge, Massachusetts, 02142. This filing is important for investors as it ensures the company's public records are accurate and up-to-date, providing transparency on its corporate identity and operational base.

Why It Matters

This filing ensures that Cullinan Oncology's public records are accurate, which is crucial for investor confidence and regulatory compliance. It confirms the company's current legal and operational details.

Risk Assessment

Risk Level: low — This filing is an administrative update and does not indicate any new financial or operational risks for the company.

Analyst Insight

Investors should note this filing as a routine administrative update, confirming corporate details. No immediate action is required based on this specific filing, but it reinforces the importance of accurate public records.

Key Numbers

• 001-39856 — Commission File Number (identifies Cullinan Oncology, Inc. with the SEC)
• 81-3879991 — IRS Employer Identification No. (identifies Cullinan Oncology, Inc. for tax purposes)
• 617-410-4650 — Registrant's Telephone Number (contact information for Cullinan Oncology, Inc.)

Key Players & Entities

• Cullinan Oncology, Inc. (company) — the registrant filing the 8-K/A
• One Main Street, Suite 1350, Cambridge, Massachusetts, 02142 (address) — the principal executive offices of Cullinan Oncology, Inc.
• CGEM (company) — the trading symbol for Cullinan Oncology, Inc.
• The Nasdaq Global Select Market (company) — the exchange where Cullinan Oncology, Inc.'s common stock is registered
• January 08, 2024 (date) — date of the earliest event reported and filing date

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CGEM The Nasdaq
• $468.3 million — tments, and interest receivable totaled $468.3 million. Consistent with prior guidance, the Co

Filing Documents

• cgem-20240108.htm (8-K/A) — 40KB
• 0000950170-24-002936.txt ( ) — 159KB
• cgem-20240108.xsd (EX-101.SCH) — 26KB
• cgem-20240108_htm.xml (XML) — 5KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. As of December 31, 2023, the Company's unaudited cash, cash equivalents, investments, and interest receivable totaled $468.3 million. Consistent with prior guidance, the Company expects its cash resources to provide runway into the second half of 2026 based on its current operating plan. The Company has not yet completed its quarter-end financial close process for the quarter ended December 31, 2023. This estimate of the Company’s cash, cash equivalents, investments, and interest receivable as of December 31, 2023 is preliminary, has not been audited and is subject to change upon completion of the Company’s financial statement closing procedures. Additional information and disclosure would be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2023. The Company’s independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to this preliminary result and, accordingly, does not express an opinion or any other form of assurance about it. The information contained in this Current Report on Form 8-K under Item 2.02 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and will not be incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, unless specifically identified as being incorporated therein by reference.

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this Current Report on Form 8-K that are not historical facts may be considered “forward-looking statements,” including statements regarding the Company’s preliminary estimates of cash, cash equivalents, investments, and interest receivable as of December 31, 2023. Forward-looking statements are typically, but not always, identified by the use of words such as “estimate,” “expect,” and other similar terminology. Any forward-looking statements in this Current Report on Form 8-K are based on management's current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause the Company's actual results, performance or achievements to be materially different from any expressed or implied by the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks related to preliminary financial results, including the risks that the preliminary financial results reported herein reflect information available to the Company only at this time and may differ from actual results, including in connection with the Company’s completion of financial closing procedures, risks associated with market conditions, risks and uncertainties associated with the Company’s business and finances in general, as well as the risks detailed in the Company’s recent filings on Forms 10-K and 10-Q with SEC. While the Company may elect to update such forward-looking statements at some point in the future, the Company disclaims any obligation to do so, even if subsequent events cause its views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subseque

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CULLINAN ONCOLOGY, INC. Date: January 8, 2024 By: /s/ Jeffrey Trigilio Jeffrey Trigilio Chief Financial Officer

View Full Filing

View this 8-K/A filing on SEC EDGAR